{"id":40683,"date":"2023-03-14T12:40:01","date_gmt":"2023-03-14T07:10:01","guid":{"rendered":"http:\/\/finservwealth.com\/jefferies-retains-39buy39-call-on-sun-pharma-with-26-upside-stays-bullish-on-concert-deal\/"},"modified":"2023-03-14T12:40:01","modified_gmt":"2023-03-14T07:10:01","slug":"jefferies-retains-39buy39-call-on-sun-pharma-with-26-upside-stays-bullish-on-concert-deal","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/jefferies-retains-39buy39-call-on-sun-pharma-with-26-upside-stays-bullish-on-concert-deal\/","title":{"rendered":"Jefferies retains #39;buy#39; call on Sun Pharma with 26% upside, stays bullish on Concert deal"},"content":{"rendered":"<p> Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031.<\/p><div id=\"finse-369347465\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-retains-39buy39-callsun-pharma26-upside-stays-bullishconcert-deal_16926271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031. Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-retains-39buy39-callsun-pharma26-upside-stays-bullishconcert-deal_16926271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-retains-39buy39-callsun-pharma26-upside-stays-bullishconcert-deal_16926271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031. Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/jefferies-retains-39buy39-callsun-pharma26-upside-stays-bullishconcert-deal_16926271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Jefferies expects Sun Pharma to leverage its existing field force to market this product and incremental spend will largely be towards promotion of the product. It forecasts that Deuruxolitinib can achieve sales of around USD 765 million in the US   EU market by 2031.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-40683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/S\/SUN-PHARMACEUTICALS-INDUSTRIES_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/40683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=40683"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/40683\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=40683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=40683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=40683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}